Ovid Therapeutics Inc.OVIDNASDAQ
LOADING
|||
R&D Expense Growth Recovery in Progress
Trending higher, below historical average, structural decline.
Left:
||||
Year-over-year research & development expense growth
Latest
28.61%
↓ 96% below average
Average (9y)
665.45%
Historical baseline
Range
High:6174.73%
Low:-47.55%
CAGR
-45.0%
Structural decline
| Period | Value |
|---|---|
| 2024 | 28.61% |
| 2023 | 16.12% |
| 2022 | -47.55% |
| 2021 | -26.79% |
| 2020 | 36.83% |
| 2019 | 38.67% |
| 2018 | -32.38% |
| 2017 | 421.30% |
| 2016 | 44.98% |
| 2015 | 6174.73% |